Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Brimo PS DDS · 1 trial · 1 indication
Implants administered during the parent study are evaluated during this study to determine if they have completely degraded. The time frame is evaluated from the point of the first treatment in the parent study.
| Arm | Type | Description |
|---|---|---|
| Brimo PS DDS® 400 μg (2 implants) | EXPERIMENTAL | Patients who received Brimo PS DDS® 400 μg (2 implants) in a previous study. |
| Brimo PS DDS® 400 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 400 μg (1 implant) in a previous study. |
| Brimo PS DDS® 200 μg (2 implants) | EXPERIMENTAL | Patients who received Brimo PS DDS® 200 μg (2 implants) in a previous study. |
| Brimo PS DDS® 200 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 200 μg (1 implant) in a previous study. |
| Brimo PS DDS® 100 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 100 μg (1 implant) in a previous study. |
| Brimo PS DDS® 50 μg (1 implant) | EXPERIMENTAL | Patients who received Brimo PS DDS® 50 μg (1 implant) in a previous study. |
| Sham | SHAM_COMPARATOR | Patients who received sham in a previous study. |
| Name | Type | Description |
|---|---|---|
| Brimo PS DDS® | DRUG | Patients who received Brimo PS DDS® intravitreal implant in a previous study. |
| Sham | OTHER | Patients who recieved sham in a previous study. |
Inclusion Criteria: * Received the most recent sham or active study treatment of intravitreal Brimo PS DDS® no later than 36 months prior to entry into this study and have either completed their previous study, or have exited early from their previous study for any reason * Applicable studies: Prev...
Brimo PS DDS is an investigational small molecule being studied in patients who participated in an intravitreal Brimo PS DDS study. It is in Phase 2 clinical development for this ophthalmology indication. The drug is not approved and remains under clinical investigation.
Brimo PS DDS is a small molecule developed by AbbVie Inc. for use in ophthalmology. Its specific molecular target has not been disclosed in the available information, so its mechanism of action is not detailed here.
Brimo PS DDS is developed by AbbVie Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker ABBV. The drug is currently in Phase 2 clinical development for an ophthalmology indication.
Brimo PS DDS is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 2 trial has been completed, and no active trials are currently listed.
Brimo PS DDS has one completed Phase 2 trial, NCT01080209, titled "Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System." The trial enrolled 215 participants across multiple countries, including the United States, Australia, and several European and Asian nations.
Brimo PS DDS is also known as the Brimonidine Tartrate Posterior Segment Drug Delivery System, as reflected in the title of its clinical trial NCT01080209. The drug is being studied for use in patients who previously participated in an intravitreal Brimo PS DDS study.